Unknown

Dataset Information

0

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.


ABSTRACT: Platinum regimens still play a key role in chemotherapy for incurable non-small cell lung cancer (NSCLC). Although guidelines list many platina regimens, the best regimens have not yet clarified. Electronic searches were carried out during November 26th-28th, 2016. We included individually randomized trials comparing two or more platinum regimes for incurable chemo-naive NSCLC published in English full papers. The platinum doublets should be either Cisplatin (CDDP), Carboplatin (CBDCA), or Nedaplatin (CDGP) plus one of the third-generation agents. The platinum triplet should be the doublet plus bevacizumab (BEV). The data were independently extracted and cross-checked by two investigators. We did not observed heterogeneity (whole network level Q?=?28.9, df?=?34, P?=?0.717) among 59 pairwise comparisons from 45 studies with 16141 cases for the primary outcome, hazard ratio for overall survival (HRos). Using CBDCA?+?Paclitaxel (PTX)?+?BEV as a common comparator, CDGP?+?Docetaxel (DTX) (HRos?=?0.98, 95%CI: 0.75-1.29, P?=?0.884), CDDP?+?Tegafur gimeracil oteracil (S1) (HRos?=?1.23, 95%CI: 0.96-1.57, P?=?0.099), CBDCA?+?S1 (HRos?=?1.23, 95%CI: 0.99-1.53, P?=?0.062), and CDGP?+?Gemcitabine (GEM) (HRos?=?1.24, 95%CI: 0.71-2.17, P?=?0.45) did not have significantly poorer HRos. We suggest that these regimens as acceptable first-choice regimens.

SUBMITTER: Horita N 

PROVIDER: S-EPMC5640659 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.

Horita Nobuyuki N   Nagashima Akimichi A   Nakashima Kentaro K   Shibata Yuji Y   Ito Kentaro K   Goto Atsushi A   Yamanaka Takeharu T   Kaneko Takeshi T  

Scientific reports 20171013 1


Platinum regimens still play a key role in chemotherapy for incurable non-small cell lung cancer (NSCLC). Although guidelines list many platina regimens, the best regimens have not yet clarified. Electronic searches were carried out during November 26th-28th, 2016. We included individually randomized trials comparing two or more platinum regimes for incurable chemo-naive NSCLC published in English full papers. The platinum doublets should be either Cisplatin (CDDP), Carboplatin (CBDCA), or Nedap  ...[more]

Similar Datasets

| S-EPMC8720615 | biostudies-literature
| S-EPMC8435382 | biostudies-literature
| S-EPMC7745559 | biostudies-literature
| S-EPMC7811416 | biostudies-literature
| S-EPMC7214664 | biostudies-literature
| S-EPMC5625762 | biostudies-literature
| S-EPMC6128034 | biostudies-literature
| S-EPMC3383686 | biostudies-literature
| S-EPMC10777972 | biostudies-literature
| S-EPMC3603584 | biostudies-literature